Beqalzi

News

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.